Overview

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

Status:
RECRUITING

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

Phase:

PHASE3

Details

Lead Sponsor:

Colorado Prevention Center

Collaborators:

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Saint Luke's Mid America Heart Institute

Treatments:

empagliflozin
finerenone